Reason for request
The actual benefit of these medicinal products is substantial.
Clinical Added Value
|no clinical added value||
LAMICTAL and LAMICSTART do not provide an improvement in actual benefit (IAB V) in the management by monotherapy of typical absence seizures in children and adolescents aged 2 to 12 years.